Cell specific interaction of pasireotide: review of preclinical studies in somatotroph and corticotroph pituitary cells.
ACTH-secreting
GH-secreting
Pasireotide
Pituitary adenomas
Primary cultures
Journal
Pituitary
ISSN: 1573-7403
Titre abrégé: Pituitary
Pays: United States
ID NLM: 9814578
Informations de publication
Date de publication:
Feb 2019
Feb 2019
Historique:
pubmed:
30
11
2018
medline:
5
3
2019
entrez:
29
11
2018
Statut:
ppublish
Résumé
Pasireotide is a second-generation somatostatin (SRIF) receptor ligand (SRL), approved for medical treatment of acromegaly and Cushing's disease (CD). The molecule is a stable cyclohexapeptide synthetized based on SRIF structure. Differently from first-generation SRLs (e.g. octreotide), preferentially binding somatostatin receptor (SST) subtype 2 (SST We aimed to highlight the differential receptor-targeted action of pasireotide in the treatment of somatotroph and corticotroph adenomas, throughout the critical revision of preclinical studies carried out on acromegaly and CD models. Different authors demonstrated that the antisecretory effect of pasireotide in somatotroph adenoma cell cultures is comparable to that of the SST The analysis of preclinical studies carried out in somatotroph and corticoph adenomas points out that pasireotide shows a cell-specific activity, exerting its biological effects via different SSTs in the different adenoma histotypes.
Sections du résumé
BACKGROUND
BACKGROUND
Pasireotide is a second-generation somatostatin (SRIF) receptor ligand (SRL), approved for medical treatment of acromegaly and Cushing's disease (CD). The molecule is a stable cyclohexapeptide synthetized based on SRIF structure. Differently from first-generation SRLs (e.g. octreotide), preferentially binding somatostatin receptor (SST) subtype 2 (SST
METHODS
METHODS
We aimed to highlight the differential receptor-targeted action of pasireotide in the treatment of somatotroph and corticotroph adenomas, throughout the critical revision of preclinical studies carried out on acromegaly and CD models.
RESULTS
RESULTS
Different authors demonstrated that the antisecretory effect of pasireotide in somatotroph adenoma cell cultures is comparable to that of the SST
CONCLUSIONS
CONCLUSIONS
The analysis of preclinical studies carried out in somatotroph and corticoph adenomas points out that pasireotide shows a cell-specific activity, exerting its biological effects via different SSTs in the different adenoma histotypes.
Identifiants
pubmed: 30483918
doi: 10.1007/s11102-018-0926-y
pii: 10.1007/s11102-018-0926-y
doi:
Substances chimiques
Receptors, Somatostatin
0
Somatostatin
51110-01-1
Adrenocorticotropic Hormone
9002-60-2
pasireotide
98H1T17066
Types de publication
Journal Article
Review
Langues
eng
Sous-ensembles de citation
IM
Pagination
89-99Références
Front Neuroendocrinol. 1999 Jul;20(3):157-98
pubmed: 10433861
Eur J Endocrinol. 2002 May;146(5):707-16
pubmed: 11980628
Virchows Arch. 2002 May;440(5):461-75
pubmed: 12021920
Endocr Rev. 2003 Feb;24(1):28-47
pubmed: 12588807
Neuroendocrinology. 2003 Sep;78(3):163-75
pubmed: 14512709
J Clin Endocrinol Metab. 2004 Apr;89(4):1577-85
pubmed: 15070915
J Clin Endocrinol Metab. 2004 Jun;89(6):3027-32
pubmed: 15181094
Am J Physiol Endocrinol Metab. 2005 Aug;289(2):E278-87
pubmed: 15769796
Eur J Endocrinol. 2005 Apr;152(4):645-54
pubmed: 15817922
J Clin Endocrinol Metab. 2006 Nov;91(11):4482-8
pubmed: 16940446
Pharmacol Ther. 2007 Nov;116(2):322-41
pubmed: 17719647
Mol Cell Endocrinol. 2008 May 14;286(1-2):192-8
pubmed: 18191325
J Mol Endocrinol. 2009 Jan;42(1):47-56
pubmed: 18852217
J Clin Endocrinol Metab. 2009 Feb;94(2):654-61
pubmed: 19001514
J Mol Endocrinol. 2009 May;42(5):361-70
pubmed: 19141603
J Clin Endocrinol Metab. 2009 Jul;94(7):2634-43
pubmed: 19401364
J Clin Endocrinol Metab. 2009 Nov;94(11):4342-50
pubmed: 19820006
Mol Endocrinol. 2010 Jan;24(1):240-9
pubmed: 19910453
Mol Endocrinol. 2010 Feb;24(2):436-46
pubmed: 20051480
Trends Endocrinol Metab. 2010 Mar;21(3):123-33
pubmed: 20149677
Mol Endocrinol. 2011 Jun;25(6):1040-54
pubmed: 21493671
Neuroendocrinology. 2011;94(2):124-36
pubmed: 21525729
Endocr Relat Cancer. 2011 Dec 01;18(6):R233-51
pubmed: 22135243
N Engl J Med. 2012 Mar 8;366(10):914-24
pubmed: 22397653
J Endocrinol Invest. 2013 Jan;36(1):38-43
pubmed: 22472799
Proc Natl Acad Sci U S A. 2012 Oct 23;109(43):17591-6
pubmed: 23045642
J Clin Endocrinol Metab. 2013 Jan;98(1):E66-71
pubmed: 23118420
J Clin Endocrinol Metab. 2013 Feb;98(2):425-38
pubmed: 23345100
Front Neuroendocrinol. 2013 Aug;34(3):228-52
pubmed: 23872332
J Clin Endocrinol Metab. 2013 Dec;98(12):E1880-90
pubmed: 24081741
J Clin Endocrinol Metab. 2013 Nov;98(11):E1730-9
pubmed: 24092823
Endocrinology. 2013 Dec;154(12):4715-25
pubmed: 24169548
J Clin Endocrinol Metab. 2014 Mar;99(3):791-9
pubmed: 24423324
Mol Cell Endocrinol. 2014 Apr 25;387(1-2):44-51
pubmed: 24565897
J Mol Endocrinol. 2014 Jun;52(3):R223-40
pubmed: 24647046
Endocrinology. 2014 Aug;155(8):2932-41
pubmed: 24828612
Mol Cell Endocrinol. 2014 Aug 25;394(1-2):37-46
pubmed: 25011056
J Clin Endocrinol Metab. 2015 Jan;100(1):122-31
pubmed: 25250634
J Clin Endocrinol Metab. 2014 Nov;99(11):3933-51
pubmed: 25356808
Acta Endocrinol (Copenh). 1989 Jun;120(6):760-6
pubmed: 2543178
Endocr Rev. 2015 Aug;36(4):385-486
pubmed: 26067718
Eur J Endocrinol. 2016 Feb;174(2):213-26
pubmed: 26578638
Eur J Endocrinol. 2016 Feb;174(2):241-50
pubmed: 26586796
Drug Des Devel Ther. 2016 Jan 11;10:227-39
pubmed: 26811671
J Endocrinol. 2016 Nov;231(2):135-145
pubmed: 27587848
Endocr Relat Cancer. 2016 Dec;23(12):R551-R566
pubmed: 27697899
Pituitary. 2017 Feb;20(1):93-99
pubmed: 27900635
J Clin Endocrinol Metab. 2017 Jun 1;102(6):2009-2018
pubmed: 28323931
Nat Rev Endocrinol. 2018 Sep;14(9):552-561
pubmed: 30050156
Pharmacol Rev. 2018 Oct;70(4):763-835
pubmed: 30232095
Life Sci. 1982 Sep 13;31(11):1133-40
pubmed: 6128648
N Engl J Med. 1983 Dec 15;309(24):1495-501
pubmed: 6139753
J Clin Endocrinol Metab. 1982 Feb;54(2):286-91
pubmed: 6274899
Eur J Endocrinol. 1994 Feb;130(2):125-31
pubmed: 8130885
Metabolism. 1996 Aug;45(8 Suppl 1):83-5
pubmed: 8769391